GILEAD SCIENCES INC (GILD)

US3755581036 - Common Stock

77.09  -0.56 (-0.72%)

After market: 77.2 +0.11 (+0.14%)

GILEAD SCIENCES INC

NASDAQ:GILD (5/26/2023, 7:27:38 PM)

After market: 77.2 +0.11 (+0.14%)

77.09

-0.56 (-0.72%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)04-27 2023-04-27/amc
Earnings (Next)07-31 2023-07-31/amc
Ins Owners0.06%
Inst Owners81.86%
Market Cap96.16B
Shares1.25B
PE11.82
Fwd PE10.42
Dividend Yield3.86%
Analysts71.89
IPO01-22 1992-01-22
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GILD Daily chart

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The firm offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The firm's other products include AmBisome and Letairis. The company also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.

Company Info

GILEAD SCIENCES INC

333 Lakeside Dr

Foster City CALIFORNIA 94404

P: 16505743000.0

CEO: Daniel P. O'Day

Employees: 17000

Website: https://www.gilead.com/

GILD News

News Image4 days ago - USA News GroupPromising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

/PRNewswire/ -- USA News Group - The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with...

News Image4 days ago - FinancialNewsMediaPromising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END

News Image4 days ago - Investor's Business DailyArcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class

Roche tested its treatment in patients with liver cancer and found "meaningful" results.

News Image4 days ago - Seeking AlphaGilead's COVID drug Veklury gets EMA greenlight for expanded use

A committee of the European Medicines Agency ((EMA)) recommended the expanded use of Gilead Sciences (GILD) COVID drug Veklury (remdesivir). Read more here

News Image4 days ago - Gilead Sciences, Inc.CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
News Image4 days ago - Gilead Sciences, Inc.Gilead Sciences to Present at Upcoming Investor Conference

GILD Twits

Here you can normally see the latest stock twits on GILD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example